CrushSCI.com
207.7Average days
182Median days
110Fastest days
344Longest days
2,7602025 publications

Paper Review Records

All Paper Review Records

6 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

160 days

Phase I Trial of IL13Rα2-Targeted CAR T-cell Therapy for Recurrent Malignant Glioma: Clinical Results and Pharmacokinetics

Authors
Kiwan Kim; Seong-Won Song; Yeongha Jeon; Soyoung Choi; Jiyoun Choi; Sungmin Jun; Ju-Hwang Park; Song-Jae Lee; Nayoung Han; Yun-Sik Dho; Sang-Hoon Shin; Heon Yoo; Kyu-Chang Wang; Ho-Shin GwakShow moreShow less
Affiliations
1. 1R&D center, CellabMED Inc., Seoul, Republic of Korea.; 2. 2CellabMED Inc., Seoul, Republic of Korea.; 3. 3CGT center, CellabMED Inc., Seoul, Republic of Korea.; 4. Samsung Medical Center 4 Department of Pathology and Translational Genomics, , Seoul, Republic of Korea.; 5. National Cancer Center 5 Neuro-oncology clinic, , Goyang, Republic of Korea.; 6. 6Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, Goyang, Republic of Korea.Show moreShow less
Source PDF DOI Publisher page
295 days

DNMT3B Plays Antagonistic Roles with SMARCB1 and Is a Targetable Vulnerability in Rhabdoid Tumors

Authors
Céline Chauvin; Ryszard Wimmer; Ludovica Brunetti; Joanna Cyrta; Ana Boranijasevic; Mamy Andrianteranagna; Julien Masliah-Planchon; Kévin Beccaria; Sandrina Turczynski; Grégory Thomson; Maëva Veyssière; Rachida Bouarich-Bourimi; Zhi-Yan Han; Owen Hoare; Aurore Coulomb; Mylène Bohec; Sylvain Baulande; Gaëlle Pierron; Olivier Delattre; Arnault Tauziède-Espariat; Nicolas Servant; Alexandre Baffet; Franck BourdeautShow moreShow less
Affiliations
1. 1INSERM U1330, Childhood Oncology Research Unit, SIREDO Oncology Center, Institut Curie Research Center, Paris, France.; 2. Institut Curie 2 , CNRS UMR144, PSL Research University, Sorbonne University, Paris, France.; 3. Institut Curie 3 Department of Pathology, , PSL Research University, Paris, France.; 4. Institut Curie 4 INSERM U900, Bioinformatics, Biostatistics, Epidemiology and Computational Systems Unit, , Mines Paris Tech, PSL Research University, Institut Curie Research Center, Paris, France.; 5. 5Somatic Genetic Unit, Department of Pathology, Diagnostic and Theranostic Medecine, Institut Curie Hospital, Paris, France.; 6. 6Department of Pediatric Neurosurgery, Necker Hospital, APHP, Université Paris Cité, Paris, France.; 7. Sorbonne Université 7 Department of Pathology, Hôpital Armand Trousseau, Assistance-Publique Hôpitaux de Paris, , Paris, France.; 8. 8Single Cell Initiative, ICGex Next-Generation, PSL Research University, Institut Curie Research Center, Paris, France.; 9. 9Department of Neuropathology, GHU Paris Psychiatry and Neurosciences, Sainte-Anne Hospital, Paris, France.; 10. 10Institut national de la santé et de la recherche médicale (Inserm), Paris, France.; 11. 11Paris Cité University, Paris, France.Show moreShow less
Source PDF DOI Publisher page
344 days

Clinical, Genomic, and Spatial Transcriptomic Features of Pancreatic Adenosquamous Carcinoma Support Subtype-Specific Therapeutic Strategies

Authors
S. Daniel Haldar; Meredith Wetzel; Jiayun Lu; Jae W. Lee; Hassan Sinan; Christopher D. Jakubowski; Fen Saj; Dean Pavlick; Ryon P. Graf; Julia Quintanilha; Gerald Li; Jerry Mitchell; Jeffrey S. Ross; Anirban Maitra; Milind Javle; Shubham Pant; Hao Wang; Richard Burkhart; Daniel A. Laheru; Elizabeth M. Jaffee; Elana J. Fertig; Elizabeth D. Thompson; Dimitrios N. Sidiropoulos; Luciane T. Kagohara; Nilofer S. AzadShow moreShow less
Affiliations
1. The University of Texas MD Anderson Cancer Center 1 Department of Gastrointestinal Medical Oncology, , Houston, Texas.; 2. 2Johns Hopkins Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.; 3. Sidney Kimmel Comprehensive Cancer Center 3 Department of Oncology, , , Baltimore, Maryland.; 4. Johns Hopkins University 3 Department of Oncology, , , Baltimore, Maryland.; 5. Sidney Kimmel Comprehensive Cancer Center 4 Division of Quantitative Sciences, Department of Oncology, , , Baltimore, Maryland.; 6. Johns Hopkins University 4 Division of Quantitative Sciences, Department of Oncology, , , Baltimore, Maryland.; 7. 5Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.; 8. Icahn School of Medicine at Mount Sinai 6 Elmhurst Hospital Center, , Queens, New York.; 9. 7Department of Oncology, Albert Einstein College of Medicine, Bronx, New York.; 10. Foundation Medicine 8 , Boston, Massachusetts.; 11. SUNY Upstate Medical University 9 , Syracuse, New York.; 12. 10Perlmutter Cancer Center, New York University Grossman School of Medicine, New York, New York.; 13. 11Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland.; 14. 12Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland.Show moreShow less
Source PDF DOI Publisher page
110 days

Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases

Authors
Benjamin L. Schlechter; Marwan G. Fakih; Apostolia M. Tsimberidou; Andrea J. Bullock; Agustin Pimentel; Sunil Sharma; Heinz-Josef Lenz; Michael S. Gordon; Ghassan K. Abou-Alfa; Thomas U. Marron; Robert W. Lentz; Wells Messersmith; Ian Chau; Bruno Bockorny; Dhan Chand; Manushak Avagyan; Wei Wu; Benny Johnson; Joseph E. Grossman; Steven J. O’Day; Anthony B. El-Khoueiry; Neil H. SegalShow moreShow less
Affiliations
1. Dana-Farber Cancer Institute , Boston, Massachusetts.; 2. City of Hope Comprehensive Cancer Center, Duarte, California.; 3. University of Texas, MD Anderson Cancer Center, Houston, Texas.; 4. Beth Israel Deaconess Medical Center , Boston, Massachusetts.; 5. University of Miami, Sylvester Comprehensive Cancer Center , Miami, Florida.; 6. HonorHealth Research Institute, Scottsdale, Arizona.; 7. University of Southern California , Norris Comprehensive Cancer Center, Los Angeles, California.; 8. Memorial Sloan Kettering Cancer Center , New York, New York.; 9. Weill Cornell Medical College, New York, New York.; 10. Trinity College Dublin, Dublin, Ireland.; 11. Mount Sinai, Tisch Cancer Center, New York, New York.; 12. University of Colorado Cancer Center , Aurora, Colorado.; 13. The Royal Marsden Hospital , London, United Kingdom.; 14. Agenus Inc. , Lexington, Massachusetts.Show moreShow less
Source PDF DOI Publisher page
133 days

FDA Approval Summary: Erdafitinib for FGFR3 -Altered Locally Advanced or Metastatic Urothelial Carcinoma

Authors
William F. Maguire; Elaine Chang; Flora Mulkey; Vicky Hsu; Huali Wu; Tien M. Truong; Dana Kappel; Jeffrey Kraft; Jingyu Yu; Xin Gao; William F. Pierce; Nam Atiqur Rahman; Mallorie H. Fiero; Laleh Amiri-Kordestani; R. Angelo de Claro; Daniel L. SuzmanShow moreShow less
Affiliations
1. U.S. Food and Drug Administration 1 Center for Drug Evaluation and Research, , Silver Spring, Maryland.; 2. 2Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland.Show moreShow less
Source PDF DOI Publisher page
204 days

Targetable S100–RAGE Signaling Mediates Intrinsic Trastuzumab Deruxtecan Resistance in Metastatic Breast Cancer

Authors
Wenjuan Dong; Shiruo Wang; Bill Chan; Matthew Vasquez; Johnny Z.M. Cui; James Sampson; Caitlin Sannes; Wei Yang; Akshjot Puri; Jenny Chang; Hong Zhao; Xiaoxian Li; Stephen T.C. WongShow moreShow less
Affiliations
1. 1Systems Medicine and Bioengineering Department, Houston Methodist Neal Cancer Center, Houston, Texas.; 2. 2Advanced Cellular and Tissue Microscopy Shared Resource, Houston Methodist Research Institute and Houston Methodist Neal Cancer Center, Houston, Texas.; 3. Texas A&M University 3 School of Engineering Medicine, , Houston, Texas.; 4. 4Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia.; 5. 5Houston Methodist Neal Cancer Center, Houston, Texas.; 6. 6Department of Medicine, Houston Methodist Hospital and Weill Cornell Medicine, New York, New York.; 7. East Carolina University 7 Department of Pathology and Laboratory Medicine, Brody School of Medicine, , Greenville, North Carolina.; 8. 8Department of Radiology, Houston Methodist Hospital and Weill Cornell Medicine, New York, New York.Show moreShow less
Source PDF DOI Publisher page

FAQ

How long does CLINICAL CANCER RESEARCH take to review a manuscript?

As of 2026-11-19, CrushSCI has 6 complete review records for CLINICAL CANCER RESEARCH. The fastest paper went from submission to acceptance in 110 days (Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases, received 2026-05-01, accepted 2026-08-19); the slowest took 344 days. The average is 207.7 days and the median is 182 days.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.